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The early closure of a clinical trial assessing the 
eﬀ ective ness of oral antiretroviral pre-exposure 
pro phyl axis (PrEP) in women, FEM-PrEP,1 is a substantial 
setback for HIV prevention. Expectations of this trial were 
high in view of favourable results from the pre-exposure 
prophylaxis initiative (iPrEX) trial,2 which studied the 
same drug and dosing strategy in men who have sex with 
men, and the Centre for the AIDS Programme of Research 
in South Africa (CAPRISA 004) trial,3 which tested 
tenofovir gel (a topical PrEP formulation) in heterosexual 
women. As a result, the interim FEM-PrEP trial results, 
announced on April 18, 2011, which showed no protection 
against HIV infection,1 were disappointing. Using 
publicly available information1 and data from other PrEP 
studies, we oﬀ er a potential explanation for the results of 
the FEM-PrEP trial.
In high HIV prevalence settings, such as sub-Saharan 
Africa, young women have disproportionately high HIV 
incidence rates, up to 8-times higher than for men of the 
same age.4 Available HIV prevention strategies provide 
few options for young women who are at high risk of 
infection but who are unable to convince their partner to 
be faithful or use condoms, underscoring the urgent 
need for a women-initiated HIV prevention technology. 
To this end, several microbicide trials have been 
undertaken during the past 17 years. Until 2010, none 
had shown protection against HIV acquisition.5 A new 
approach was needed. Antiretroviral drugs, already 
shown to be eﬀ ective in treating HIV infection and 
prevention of mother-to-child transmission, heralded a 
new option to prevent sexual transmission.
FEM-PrEP was a phase 3, double-blind, randomised, 
placebo-controlled trial assessing the eﬀ ectiveness of 
daily oral tenofovir disoproxil fumarate and emtricitabine 
for prevention of HIV acquisition in women 
aged 18–35 years in South Africa, Kenya, and Tanzania. 
At a scheduled interim analysis, the HIV incidence rate 
was 5 per 100 person-years in the 1951 women enrolled, 
and the 56 HIV endpoints were equally distributed 
between the study groups.1 Continuation of the study to 
the planned 72 HIV endpoints in an attempt to show 
eﬀ ectiveness was deemed futile, so the decision was 
made to undertake an orderly closure of the trial.
Why did the FEM-PrEP trial not show protection 
against HIV infection? To conclude that oral tenofovir 
disoproxil fumarate and emtricitabine does not prevent 
HIV infection in women would be overly simplistic and 
premature; several possible explanations exist for the 
reported primary HIV outcome in the trial. Such results 
could have occurred by chance in a trial of a truly eﬀ ective 
product, but the chance of observing no eﬀ ectiveness if 
the drug is truly 50% protective against HIV is about 3 in 
1000. However, two of the most plausible explanations 
for the trial results are low pill adherence and inadequate 
drug concentrations at the site of infection—ie, the 
genital tract.
Adherence and drug distribution are only two of the 
many components of the pathway that is intended to 
end with antiretroviral drugs preventing the development 
of HIV infection after viral exposure in the female 
genital tract. However, they are both crucial for the 
desired outcome. Adherence levels are dependent on 
human behaviour in the context of the user’s social 
environment, whereas the available concentration of the 
drug is aﬀ ected by its pharmacological properties and 
host-cell biology.
Although reported adherence in the FEM-PrEP trial 
was high,1 its accuracy cannot be assessed at this time. 
Blood concentrations of the drugs in women assigned 
to tenofovir disoproxil fumarate and emtricitabine and 
analysis of eﬀ ectiveness, stratiﬁ ed by adherence levels, 
will provide a more reliable indication of pill adherence 
during the trial. A comparison of drug concentrations 
in the women who developed HIV infection with those 
in appropriately selected controls who remained 
uninfected during the course of the trial could likewise 
provide useful clues. In the meantime, exploration of 
alternate explanations is important, in the event that 
low adherence does not fully account for the 
trial’s outcome.
Tenofovir and emtricitabine concentrations in genital 
and rectal tissues have been assessed in previous phase 1 
and pharmacokinetic studies of the oral preparation and 
tenofovir gel. With orally administered drug, the median 
cervicovaginal ﬂ uid concentration of tenofovir and 
emtricitabine at the end of the 24 h dosing interval was 
68 ng/mL (IQR 28–112) and 596 ng/mL (537–644), 
respectively.6 Vaginal tissue concentrations of tenofovir 
and emtricitabine were 7 ng/g and 63 ng/g (ng/g is 
roughly equivalent to ng/mL), respectively.7
These concentrations from oral dosing are substantially 
lower than vaginal concentrations achieved with topical 
tenofovir gel or rectal concentrations from oral tenofovir 
disoproxil fumarate and emtricitabine. The median 
cervicovaginal ﬂ uid concentration of tenofovir at the end 
of the 24 h gel dosing interval was 100 000 ng/mL and 
the vaginal tissue concentration was 7000 ng/g.8 Rectal 
tissue concentrations of tenofovir and emtricitabine 24 h 
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after a single dose of the oral drug were 1877 ng/g and 
124 ng/g, respectively.
Since tenofovir diphosphate and emtricitabine 
triphosphate are the metabolites of the parent drugs that 
inhibit viral replication, their intracellular tissue 
concentrations after oral and topical dosing could be 
informative. Although threshold concentrations for 
protection against HIV infection have not yet been 
established, data from an ex-vivo colorectal biopsy 
infection model9 suggest that at least 1000 fmol/mg of 
tenofovir diphosphate could be needed for near complete 
protection. The concentrations of this metabolite 24 h 
after one oral dose of tenofovir disoproxil fumarate and 
emtricitabine were 206 fmol/mg in rectal tissue and only 
about 2 fmol/mg in vaginal tissue.7 By comparison, the 
tenofovir diphosphate concentrations 24 h after one 
tenofovir gel dose were about 1000 fmol/mg in vaginal 
tissue and roughly 10 000 fmol/10⁶ cervical cells obtained 
from cytobrush sampling.8 In short, tenofovir diphosphate 
concentrations are about 100-fold higher in rectal than 
vaginal tissues with oral tenofovir disoproxil fumarate 
and emtricitabine, and about 1000-fold higher in vaginal 
tissues with tenofovir gel than with oral tenofovir 
disoproxil fumarate and emtricitabine (table).
To gain insight into the potential threshold tenofovir 
concentrations needed to prevent HIV infection in 
women, we assessed tenofovir concentrations in 
undiluted aspirated cervicovaginal ﬂ uid with a validated 
ultra performance liquid chromatograph-mass spec-
trometry method in women assigned to tenofovir gel in 
the CAPRISA 004 trial.3 Samples were available from the 
ﬁ rst study visit post infection from 34 of the 38 HIV 
seroconverters and from a randomly selected study visit 
from 301 women assigned to tenofovir gel who remained 
uninfected during the trial.
With data from this trial,3 HIV incidence in women 
with tenofovir concentrations of 1000 ng/mL or less 
(n=253) and those with tenofovir concentrations of 
1000 ng/mL or more (82) was compared with that in the 
placebo gel group (ﬁ gure). The HIV incidence rate in 
women with tenofovir concentrations of 1000 ng/mL or 
less was close to that in the placebo group (7·8 vs 9·1 per 
100 women-years; incidence rate ratio [IRR]=0·86, 
95% CI 0·54–1·35, p=0·51). However, the HIV incidence 
rate in women with tenofovir concentrations greater than 
1000 ng/mL was signiﬁ cantly lower than that in the 
placebo group (2·4 vs 9·1 per 100 person-years; IRR=0·26, 
95% CI 0·05–0·80, p=0·01). Adjustment for age, study 
site, duration of study participation at the point when 
tenofovir concentration was measured, sexual frequency, 
and condom use did not materially change this ﬁ nding.
These tenofovir concentrations are proxy markers of 
drug exposure at the actual time of HIV exposure, and 
some residual systematic diﬀ erences between the three 
groups of women could account for some of the variations 
in HIV risk, despite adjustment for potential confounders. 
Notwithstanding, our data suggest that cervicovaginal 
ﬂ uid concentrations of tenofovir greater than 1000 ng/mL 
were required to prevent HIV infection. This value is 
more than ten times the concentration seen with oral 
tenofovir disoproxil fumarate and emtricitabine.
What are the implications for HIV prevention research? 
Detailed analyses of the FEM-PrEP1 data will undoubtedly 
enhance our understanding of how antiretrovirals prevent 
HIV infection in women. In the interim, our suggestions 
for continuing and proposed PrEP research are: ﬁ rst, the 
eﬀ ectiveness trials that are underway (registered with 
ClincalTrials.gov, numbers NCT00705679, NCT00557245, 
NCT00448669, NCT00119106) for tenofovir disoproxil 
fumarate alone and in combination with emtricitabine 
are crucially needed to corroborate or refute the 
FEM-PrEP1 trial results and to provide information about 
HIV eﬀ ectiveness in diverse populations, various 
Vaginally administered 
1% tenofovir gel
Orally administered tenofovir 
disoproxil fumarate
Blood
Plasma7,8,10,11 ~1–10 ng/mL 25–50 ng/mL
Peripheral blood mononuclear cell11 <10 fmol/10⁶ cells ~70 fmol/10⁶ cells
Mucosal ﬂ uid
Cervicovaginal7,8,10 ~10⁵–10⁶ ng/mL ~70 ng/mL
Tissue
Vaginal (tenofovir)7,8,10,11 ~10³–10⁴ ng/g 10 ng/g
Vaginal (tenofovir diphosphate)7,8,10,11 ~10³ fmol/mg 1–10 fmol/mg
Cytobrush cells (tenofovir diphosphate)8,11 ~10⁴–10⁵ fmol/10⁶ cells ~10³ fmol/10⁶ cells
Rectal (tenofovir)7,11 NA 2000 ng/g
Rectal (tenofovir diphosphate)7,11 NA 100–1000 fmol/mg
PBMC=peripheral blood mononuclear cell. NA=not available.
Table: Tenofovir concentrations measured in blood, mucosal ﬂ uid, and tissue 24 h after topical or 
oral administration
Figure: HIV infection rates in women in the CAPRISA 004 trial3
Women assigned to tenofovir gel are stratiﬁ ed by cervicovaginal ﬂ uid concentrations of tenofovir.
*Log rank comparing women with tenofovir concentrations greater than 1000 ng/mL versus placebo.













































Tenofovir gel ≤1000 ng/mL
Tenofovir gel >1000 ng/mL
Placebo gel
Tenofovir gel ≤1000 ng/mL
Tenofovir gel >1000 ng/mL
p=0·01*
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formulations, and in diﬀ erent routes of transmission. 
Researchers need to factor the FEM-PrEP trial outcome 
into the information provided to participants. Furthermore 
the data-review plans, especially the rules for futility, 
might need to be revisited.
Second, investigators need to revise existing or develop 
new animal-challenge and tissue models for PrEP to be 
able to assess varying drug dosages. Speciﬁ cally, further 
animal models with which to assess vaginal challenge 
after oral dosing are needed. Additonally, the models 
might need an infectious virus inoculum that is closer to 
physiological values. Third, until there is improved clarity 
about the threshold concentration of tenofovir that is 
likely to protect against HIV, the goal in future clinical 
trials of this drug should be to attain the highest tolerable 
drug concentrations in the vagina. Options such as 
combinations of oral and topical formulations could be 
worth investigation, especially in settings in which anal 
sex is common in women. Fourth, eﬀ orts to enhance 
adherence in PrEP trials are crucial. Finally, new PrEP 
formulations, such as intravaginal rings and injectables, 
will need to be carefully assessed to work out whether the 
drug concentrations achieved at the site of viral exposure 
are likely to be high enough to prevent HIV infection.
The FEM-PrEP trial is a sharp reminder of the 
uncertainty of the scientiﬁ c endeavour. Success needs an 
iterative approach to identify the most appropriate drugs, 
drug concentrations, adherence support, formulations, 
and dosing regimen for each route of HIV transmission. 
The proof of principle that antiretroviral drugs can prevent 
sexual transmission of HIV has reinvigorated HIV 
prevention. It has created new hope that antiretroviral-
based PrEP strategies, especially those that are women-
initiated, could in combination with other prevention 
interventions, ﬁ nally stem the tide of the HIV pandemic.
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